Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.75M | $7.38M | $7.35M | $11.2M | $12.8M | $16.3M | $20.6M | $24.0M | $31.4M | $37.0M |
| Revenue growth | — | 28.4% | -0.4% | 52.5% | 14.4% | 27.0% | 26.1% | 16.6% | 31.0% | 17.8% |
| Gross profit | — | — | — | — | $9.12M | $11.1M | $13.5M | $13.6M | $19.1M | $22.7M |
| Gross margin | — | — | — | — | 71.1% | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating income | -$7.49M | -$6.34M | -$5.25M | -$4.59M | -$6.22M | -$13.4M | -$16.3M | -$22.4M | -$19.7M | -$24.2M |
| Operating margin | -130.3% | -85.9% | -71.4% | -41.0% | -48.5% | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Net income | -$8.07M | -$7.17M | -$6.16M | -$5.54M | -$6.78M | -$14.4M | -$16.4M | -$22.1M | -$18.9M | -$25.5M |
| Net margin | -140.4% | -97.1% | -83.8% | -49.4% | -52.9% | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (diluted) | -$2.93 | -$0.93 | -$0.56 | -$0.42 | -$0.43 | -$0.69 | -$0.68 | -$0.90 | -$0.70 | -$0.90 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.82M | -$5.99M | -$4.63M | -$2.85M | -$7.81M | -$12.7M | -$16.2M | -$13.7M | -$8.95M | -$23.9M |
| Capital expenditures | $101K | $26.8K | $63.5K | $10.0K | $41.0K | $168K | $253K | $717K | $275K | $522K |
| Free cash flow | -$5.92M | -$6.02M | -$4.69M | -$2.86M | -$7.85M | -$12.9M | -$16.4M | -$14.4M | -$9.22M | -$24.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.32M | $9.29M | $3.10M | $5.70M | $20.1M | $54.1M | $27.6M | $23.1M | $20.1M | $45.9M |
| Total assets | $7.40M | $13.9M | $7.86M | $11.9M | $29.5M | $65.6M | $55.5M | $42.7M | $39.2M | $97.7M |
| Total liabilities | $8.16M | $8.07M | $6.35M | $7.34M | $27.1M | $16.8M | $18.6M | $21.5M | $13.8M | $69.7M |
| Long-term debt | $4.49M | $4.92M | $3.48M | $2.07M | $21.3M | $9.84M | $9.89M | $9.95M | — | $49.1M |
| Shareholders' equity | -$756K | $5.83M | $1.51M | $4.59M | $2.38M | $48.8M | $36.9M | $21.2M | $25.4M | $28.0M |
| Retained earnings | -$93.9M | -$101M | -$107M | -$113M | -$120M | -$134M | -$150M | -$172M | -$191M | -$217M |
| Shares (wtd avg diluted) | 3.62M | 10.7M | 11.0M | 15.2M | 17.0M | 20.7M | 24.2M | 24.6M | 27.0M | 28.3M |
Every figure is extracted from ClearPoint Neuro, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.